SAKK 06/19: adding intravesical BCG to perioperative chemoimmunotherapy in MIBC

Phase 1-2 · MedPage Today · 2026-10-01. Number 4 in the UrologyWatch Top 5 for October 2, 2026.

Primary analysis of the single-arm, open-label phase II SAKK 06/19 trial, which added intravesical recombinant BCG to perioperative chemoimmunotherapy in high-risk muscle-invasive bladder cancer.

Why it matters: An early-phase signal only: without a randomized control arm, the trial cannot show how much intravesical BCG adds.

Source: MedPage Today · PubMed 42212670 · DOI 10.1200/jco-26-00845

The full October 2, 2026 edition · Today's urology news